Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19780238 | 1.00 | AKR1B1 (0.37) | AKR1B1RECQLCES2CES1 | |
| SCHEMBL28403114 | 0.80 | ACHE (0.38) | CES2CES1 | |
| SCHEMBL30995251 | 0.80 | ACHE (0.38) | CES2CES1 | |
| Hydrochloric Acid SCHEMBL28407167 | 0.78 | ACHE (0.37) | CES2CES1 | |
| SCHEMBL19880524 | 0.76 | RECQL (0.30) | RECQL | |
| SCHEMBL21883581 | 0.76 | HPGD (0.41) | AKR1B1 | |
| SCHEMBL19768992 | 0.75 | GABRA1 (0.41) | RECQL | |
| SCHEMBL19779453 | 0.75 | GABRA1 (0.41) | RECQL | |
| SCHEMBL19880461 | 0.74 | RPS6KA3 (0.33) | AKR1B1 | |
| SCHEMBL19769006 | 0.74 | RPS6KA3 (0.33) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896432-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | AKR1B1 4073/4885RECQL 3768/4885CES2 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.